There have been reports indicating that selective blockers of SphK2 induce autophagy in tumor cells of kidney, prostate, breast, and T-cell acute lymphoblastic leukemia, ultimately resulting in nonapoptotic cell death and delayed tumor development [134–136]. Here, SPHK2 is linked to neoplasm.